Max

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Max

What is Max? (Ambroxol)

Property Description
Active Ingredient Ambroxol hydrochloride
Form Oral solution, Syrup, Tablets
Pharmacological Class Mucolytic agent and Secretolytic agent
General Purpose Managing conditions with abnormally thick mucus
Origin Synthetic drug (benzylamide derivative)

Max (Ambroxol): Definition and Pharmacological Classification

The medication Max is defined by its core active ingredient, Ambroxol, which is a synthetic drug derived from bromhexine. It is classified pharmacologically as a mucolytic agent and secretolytic agent, designating its specific function in managing respiratory secretions. This pharmacological action is recognized for its role in modifying mucus structure within the respiratory tract.

The active component, Ambroxol hydrochloride, is the precise chemical form of the compound used in these preparations and is categorized as an aromatic amine. The primary role of this compound is increasing the quality and quantity of pulmonary surfactant, which is essential for healthy breathing mechanics. Max is typically available as a single-ingredient product, focusing on the physiological function of its core component to manage tenacious secretions.


Composition and General Purpose

The essential component of the preparation is Ambroxol hydrochloride, which is formulated into various dosage form(s) including Syrup, Oral solution, and Tablets. These forms allow for appropriate Oral administration. The brand Max often features specific flavorings in its liquid forms, a feature designed to enhance palatability, particularly for the pediatric population. The formulation is designed to be rapidly absorbed after oral administration.

The general purpose of Max is to promote a more productive cough by actively reducing the stickiness and density of mucus, a process known as secretolysis. This action is achieved by Ambroxol chemically breaking down the fibrous components of mucus, resulting in a decreased viscosity of the secretions. Ambroxol preparations are intended for use in conditions involving difficulty coughing up thick bronchial secretions. The medication's primary benefit is making thick phlegm easier to move from the airways, relieving the associated congestion.

Regulatory References

  1. Ambroxol - Drugs and Lactation Database (LactMed) - NCBI Bookshelf - NIH
  2. Ambroxol and bromhexine-containing medicines - referral

What side effects are possible with Max?

Possible side effects and safety information

The safety profile for Max (Ambroxol) is documented by regulatory authorities, classifying possible reactions primarily across the gastrointestinal and nervous systems. These effects are grouped by their official frequency classification.


Frequency-Classified Adverse Reactions

Adverse reactions listed as Common (occurring in 1 in 100 to 1 in 10 people) typically involve gastrointestinal symptoms like nausea and diarrhoea, along with sensory disturbances such as oral hypoesthesia (numbness of the mouth) and dysgeusia (taste disturbance). Effects such as vomiting, abdominal pain, and dry mouth are classified as Uncommon.

Rare adverse reactions include signs of immune response, such as general hypersensitivity reactions, rash, and urticaria.


Serious Adverse Reactions and Safety Constraints

Regulatory documents also detail severe, though infrequently reported, reactions. These include serious Anaphylactic reactions (e.g., anaphylactic shock, angioedema) and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome/Toxic Epidermal Necrolysis (SJS/TEN). The frequency of these serious events is classified as Not known (cannot be estimated from available data).

Specific safety constraints are noted for certain patients. Caution is required in individuals with severe hepatic impairment or renal impairment. Similarly, caution is advised for patients with a history of peptic or duodenal ulcers. The label also notes that co-administration with cough suppressants may potentially lead to an obstruction of the airways due to the accumulation of secretions.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Max (Ambroxol) establishes the required response to a suspected overdose and describes the expected clinical presentation.

Documented Overdose Manifestations

Overdose manifestations are primarily described as extensions of known undesirable effects. This presentation includes gastrointestinal symptoms such as diarrhoea, nausea, vomiting, and heartburn, alongside central nervous system effects such as restlessness. Historically, specific or severe life-threatening symptoms have not been recorded in human cases of overdose. The potential for the accumulation of metabolites is a specific consideration noted for patients with severe renal failure in an overdose scenario.

Regulatory Mandate for Urgent Action

Individuals are required to seek emergency medical treatment or contact a doctor immediately upon suspicion of having taken more than the recommended dosage. This action is mandated because no specific antidote is known for Max. Management is defined by regulatory bodies as strictly symptomatic and supportive measures.

Interventional procedures, such as gastric lavage, are only officially considered in extreme cases of very high overdose and if implemented within the first two hours following ingestion. The patient must be monitored to ensure vital functions are maintained and symptomatic therapy is administered.

Therapeutic Uses of Max

What Max Treats: Main Uses and Benefits

Max is generally relevant for easing symptoms that interfere with daily functioning in respiratory conditions where clearing mucus is difficult.

Easing Impaired Mucus Transport and Viscid Phlegm

Max is commonly used across conditions presenting with acute episodes and recurrent manifestations that involve a productive cough with sputum that is excessively thick or sticky. This applies to conditions such as acute and chronic bronchitis, exacerbations of chronic obstructive pulmonary disease (COPD), and as supportive care in conditions like pneumonia and bronchiectasis. The core symptomatic benefit supports the management of symptoms that create noticeable functional strain, and may assist with expectoration and contributes to improved comfort by easing associated chest congestion.

Targeted Relief for Symptomatic Discomfort

Max is also relevant for a distinct, short-term therapeutic benefit for acute, localized symptoms: the easing of pain and discomfort in the throat. This local symptomatic effect is relevant during the initial, painful phases of upper respiratory infections, offering temporary assistance in supporting symptom comfort and supports patients in addressing challenges like difficulty swallowing.


Quick Fact: Easing Symptoms of Thick Phlegm

This medication contributes to easing the overall symptom load when symptoms are related to physical discomfort and is also applied in scenarios where additional management of acute, localized throat discomfort is required.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Max (Ambroxol)

The medicine Max is defined for population use based on strict regulatory eligibility criteria, encompassing age, coexisting conditions, and physiological state.

Category Official Regulatory Status
Populations for whom use is allowed Adults and adolescents (generally 12 years) are eligible for standard use. Children are approved for use typically starting from 2 years of age for mucolytic therapy.
Populations for whom use is contraindicated Max is contraindicated in patients with known hypersensitivity to Ambroxol or excipients. It is also contraindicated in children under 2 years for the labeled indication and in patients with certain rare hereditary intolerances (e.g., fructose/galactose).
Eligibility-related restrictions Patients with severe renal impairment or severe hepatic impairment must use Max only with caution and under medical supervision. Caution is also advised for those with a history of peptic ulcers or compromised airways motility.
Pregnancy and lactation eligibility status Use is not recommended during the first trimester of pregnancy. It is also not recommended during lactation as the active substance is excreted into breast milk.

Connection to the Overall Eligibility Profile

Regulatory documents establish absolute prohibitions based on hypersensitivity and specific metabolic disorders. Eligibility is also restricted by age thresholds, strictly prohibiting use in children under 2 years for the labeled indication. Furthermore, patients with severe liver or kidney impairment are eligible only under conditions of medical caution and supervision.

What should I know about interactions with other medicines?

Max Interactions with other medicines and products

The interaction profile for Max (Ambroxol), as established in government regulatory documents, is characterized by highly specific drug-drug effects and constraints relating to clearance, with no general clinically relevant unfavorable interactions reported. This information defines necessary administration limits and pharmacokinetic outcomes.

Category Official Regulatory Statement
Contraindicated Combinations Co-administration with Antitussive Agents (e.g., Codeine) is formally restricted and not recommended by regulatory sources.
Interaction Mechanism / Restriction This constraint is based on pharmacodynamic antagonism, which risks excessive accumulation of sputum in the airways due to suppression of the cough reflex while secretions are being promoted.
Exposure Modification Co-administration with certain Antibiotics (Amoxicillin, Cefuroxime, Erythromycin, and Doxycycline) is documented to lead to higher antibiotic concentrations in bronchopulmonary secretions.
Population-Specific Note In cases of severe hepatic or renal impairment, clearance of Ambroxol or its metabolites is expected to be reduced, potentially leading to accumulation.

Connection to the Overall Interaction Profile:

Regulatory documentation defines the interaction structure by imposing one major combination restriction against cough suppressants based on a risk of secretion accumulation. The profile also formally documents a specific pharmacokinetic effect that results in increased local concentration of certain co-administered antibiotics and includes a necessary caution regarding altered clearance in populations with severe organ impairment.

Mechanism of Action

Max is an aminobisphosphonate that exhibits high affinity for the mineralized bone matrix, specifically binding to hydroxyapatite crystals at sites of active bone resorption. Once internalized by osteoclasts—the cells responsible for dissolving bone tissue—Max interferes with key intracellular metabolic pathways. The primary mechanism involves inhibiting the enzyme farnesyl pyrophosphate synthase (FPPS) within the mevalonate pathway. Inhibition of FPPS prevents the prenylation of small signaling GTPases, such as Ras, Rho, and Rac. This lack of proper prenylation disrupts the cytoskeletal organization, membrane ruffling, and vesicular trafficking essential for osteoclast function and survival. The resultant cellular cascade leads to a functional inactivation and programmed cell death (apoptosis) of the osteoclasts, thereby modulating the overall rate of bone matrix degradation on a systemic physiological level.

Dosage and Administration Information

How Max is Used — Official Administration Guidelines

The use of Max (Ambroxol) follows a standardized protocol. The approved route of administration for all common forms, including tablets, syrups, lozenges, and extended-release capsules, is oral.

The dosing schedule for adults using immediate-release preparations typically begins with 30 mg taken three times daily, often reducing to a maintenance dose of 30 mg twice daily. The maximum daily intake is generally limited to 120 mg. Alternatively, extended-release capsules may be taken as a single 75 mg dose once daily.


Administration Condition Official Instruction
Timing Should generally be taken after meals.
Preparation Liquid forms must be measured using the attached dosing device.
Hydration Adequate liquid intake must be ensured throughout the day to support proper administration.
Special Handling Extended-release capsules must be swallowed whole (not crushed or chewed).

Specific population adjustments are required for use. For patients with severe hepatic or renal impairment, the dose must be reduced or the interval between doses extended to prevent accumulation. Pediatric dosing is determined by age or weight, typically utilizing the liquid solution forms.

If a dose is missed, standard practice involves taking only the next dose at the regularly scheduled time, without taking a double dose to compensate. The duration of treatment for acute symptoms is generally short-term; medical review is advised if symptoms do not improve after approximately 5 to 14 days.

Recent Clinical Evidence

Research evidence / Overview of Studies for Max (Ambroxol)

Evidence for Viscid Respiratory Secretions and Mucus Management

Research examining viscid respiratory secretions has drawn mainly on Randomized Controlled Trials (RCTs) and systematic reviews. These studies monitored outcomes related to the body's natural processes for clearing the airways, including assessment of patient-reported experiences. The studies monitored outcomes related to physical discomfort, such as cough severity and the difficulty of expectoration (coughing up mucus), which were often tracked using specific patient scores. The observed populations included adults and older adults experiencing conditions characterized by fluctuating or episodic manifestations, such as chronic or acute bronchitis.

Findings describe patterns observed in these studies, where research highlights changes measured during the study period related to how symptoms evolved in the observed populations. One limitation is that many studies involved using Max as part of a combination regimen, often alongside antibiotics. The combination therapy design was associated with research where findings related to Max alone were complex to assess. Furthermore, findings were mixed when researchers explored objective measures like pulmonary function metrics (such as FEV1) across different observed populations.

Evidence for Acute Localized Throat Discomfort

The evidence base for Max used in acute, localized throat discomfort is founded on research primarily involving pooled analyses of multiple short-term Randomized Controlled Trials (RCTs). This research explored short-term symptom changes, focusing on temporary physiological imbalance in the throat. Studies examined outcomes related to episodic or acute changes by monitoring specific patient-reported outcomes describing perceived discomfort. Research describes how the trials measured changes in pain intensity scores, monitoring changes over defined time intervals.

Uncertainty remains regarding the durability of these observations. The follow-up durations were limited, as the studies focused on the immediate and very short-term effect. There is limited information for long-term outcomes, and the scope was restricted to short-term local symptomatic patterns.

Key Studies & References

  1. Ambroxol hydrochloride spray (Luo Runchang®) in the treatment of acute respiratory infectious diseases: a prospective, multicenter, open label, randomized controlled study (Pediatric data)

Frequently Asked Questions (FAQ)

Common questions about Max (FAQ)


Q: Is Max considered a high-risk medication?

Official regulatory documents list warnings regarding rare, severe skin reactions, such as Stevens-Johnson Syndrome. Additionally, caution is noted for patients who have pre-existing severe impairment of the liver or kidney function. The overall safety profile is determined based on adherence to the official administration instructions.


Q: Does Max have any food restrictions or dietary recommendations?

Regulatory documents state that Max should generally be taken after meals. The official product information does not specify any food restrictions or dietary recommendations beyond this timing instruction.


Q: Are there any long-term effects of taking Max that I should know about?

Regulatory data includes information from studies that reported the drug was well-tolerated in some populations during treatment periods lasting up to two years. The appropriate duration of use for a specific condition is determined by a healthcare provider.


Q: What kind of studies have been done on the safety of Max?

Safety is assessed through standard non-clinical studies, including tests for toxicity, genotoxicity, and carcinogenicity using animal models. This is supplemented by clinical trial data and ongoing reviews of human safety information (pharmacovigilance).


Q: What organs in the body are most affected by Max?

The pharmacological action of the drug is focused on managing secretions in the respiratory tract. Official guidance states that caution is required in patients with severe impairment of the liver or kidneys because these organs are responsible for clearing the drug from the body, and impairment could lead to drug accumulation.


Q: Do you have to take Max forever, or is it a short-term treatment?

The treatment is generally short-term for acute conditions, with medical review advised if symptoms do not improve after 5 to 14 days. Regulatory data includes information from studies where the drug was used continuously for up to two years for certain conditions.


Q: Does taking Max impact fertility or pregnancy planning?

Studies in animals do not indicate any direct harmful effects on fertility. However, the use of Max is not generally recommended during the first three months of pregnancy (first trimester) or while breastfeeding.


Q: What should I do if the side effects of Max bother me?

If you experience any side effects that persist or become severe, or if you notice any signs of a serious allergic reaction, official patient information states that immediate advice should be sought from a healthcare professional.


Q: Are there any known drug classes that Max should not be combined with?

Official guidance restricts combining Max with Antitussive Agents, which are medicines used to suppress coughing. This restriction is based on the risk of excessive mucus accumulation. Max may also increase the local concentration of certain Antibiotics (e.g., Amoxicillin, Erythromycin) in the bronchial secretions.


Q: Can Max be split or crushed to make it easier to swallow?

Extended-release capsules should not be crushed or chewed; they must be swallowed whole to ensure the medicine releases correctly over time. For other forms like tablets and liquid, follow standard administration practice, ensuring liquid forms are measured with the attached dosing device.


Q: How does Max's use differ from how it was used in clinical trials?

Research used to establish the drug's efficacy often involved Max as part of a combination regimen, typically alongside antibiotics. This differs from its general use as a stand-alone medicine for managing mucus.


Q: Why is close medical supervision needed when starting Max?

Close medical supervision is required for patients with severe kidney or liver impairment and those with a history of peptic ulcers due to the potential for altered drug clearance or effects on the gastric mucosal barrier.


Q: Why is the mechanism of action for Max described as complex?

The mechanism involves disrupting complex internal cellular pathways. This includes inhibiting the farnesyl pyrophosphate synthase (FPPS) enzyme, a process that affects cell function and survival.


Q: Are there any required health checks before starting Max?

Official guidance advises caution in specific patient groups, such as those with severe hepatic (liver) or renal (kidney) impairment, or a history of peptic ulcers. This implies that a necessary health assessment is performed to check for these conditions before beginning treatment.


Q: How does Max affect the immune system?

Max can affect the immune system by potentially causing rare adverse reactions. These reactions include general hypersensitivity reactions (like a rash) and serious, though infrequent, Anaphylactic reactions.


Q: How quickly does Max typically start to work?

According to official product information, Max typically starts to exert its action within approximately 30 minutes after being taken by mouth.


Q: Why do some people report feeling tired after starting Max?

Official regulatory documents list fatigue (a feeling of general tiredness or malaise) as a possible adverse effect that has been reported by some users.


Q: Does Max affect the results of common blood tests?

There is no general warning in official documents about interference with routine blood tests. However, some scientific research indicates that the active ingredient may influence cell signaling pathways related to platelet-derived growth factors.


Q: Is it normal to feel a bit dizzy in the first week of taking Max?

Official product information lists dizziness and headache as potential adverse effects that have been reported by some individuals taking the medication.


Q: How is Max eliminated from the body?

Max is processed (metabolized) in the liver, primarily through a process called glucuronidation. The resulting breakdown products (metabolites) are then predominantly eliminated from the body via the urine.


Q: What if I experience side effects that are not listed in the official documents?

The patient information leaflet states that medical advice should be sought immediately if any new or unlisted skin or mucosal lesions occur, or if you have any signs of a serious allergic reaction.


Q: How long does Max stay in your system after the last dose?

According to pharmacokinetic data, the time required for the drug concentration to decrease by half (terminal elimination half-life) is approximately 8 to 10 hours after repeated dosing.


Q: What are the restrictions on activities like driving while taking Max?

Official regulatory advice suggests that Max generally does not interfere with the ability to drive or use machinery. However, since the drug can occasionally cause side effects such as dizziness, fatigue, and headache, caution is advised if you experience these effects.


Q: What does 'contraindication' mean in the context of Max?

A contraindication is a medical term that means the medication should not be used under a specific circumstance, such as a known hypersensitivity to Max. This indicates that the risk of harm is considered greater than any potential benefit.

How should Max be stored and disposed of?

How to Store and Dispose of Max (Ambroxol)

The storage and disposal of Max (Ambroxol) must adhere strictly to official regulatory guidelines to ensure stability and safety.


Storage Requirements

Max must be stored at a temperature not exceeding 30°C and should be protected from light. The container must be kept tightly closed. For liquid formulations, the medicine has a limited in-use stability and must be discarded one month after first opening.

Child Safety

For the safety of the household, the medicine must be stored out of the reach of children.

Disposal Instructions

Do not dispose of Max with household garbage or allow it to enter the sewage system. Unused or expired product must be discarded in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Max found in:

A-Z Index: